Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...3940414243444546474849...136137»
  • ||||||||||  Review, Journal, Immune cell:  miRNAs as the important regulators of myasthenia gravis: involvement of major cytokines and immune cells. (Pubmed Central) -  Mar 31, 2023   
    Recently, other studies have revealed the potential role of various microRNAs (miRNAs) in the development of MG through different mechanisms and have proposed these molecules as effective biomarkers for the treatment of MG. This review was aimed at providing an overview of the critical regulatory roles of various miRNAs in the pathogenesis of this autoimmune disease focusing on human MG studies and the interaction between different miRNAs with important cytokines and immune cells during the development of this autoimmune disease.
  • ||||||||||  pyridostigmine Bromide / Generic mfg.
    Journal:  Epidemiology of myasthenia gravis in the province of Ourense (Galicia, Spain). (Pubmed Central) -  Mar 31, 2023   
    This review was aimed at providing an overview of the critical regulatory roles of various miRNAs in the pathogenesis of this autoimmune disease focusing on human MG studies and the interaction between different miRNAs with important cytokines and immune cells during the development of this autoimmune disease. The prevalence of MG in our health district is one of the highest published figures, and the disease is highly prevalent in the older population.
  • ||||||||||  Journal:  Central role of macrophages and nucleic acid release in Myasthenia Gravis thymus. (Pubmed Central) -  Mar 29, 2023   
    These results suggest that the decrease of thymic macrophages in AChR-MG impairs the elimination of apoptotic thymocytes favoring the release of endogenous nucleic acids from necrotic thymocytes. In this inflammatory context, thymic epithelial cells may overexpress IFN-?, which specifically induces ?-AChR, resulting in self-sensitization and thymic changes leading to AChR-MG.
  • ||||||||||  Journal:  Seasonal Variation in Neurologic Hospitalizations in the United States. (Pubmed Central) -  Mar 29, 2023   
    Seasonal variation is present across the spectrum of acute neurologic disease, including some conditions for which seasonality has not previously been described, and can be examined using multiple different methods. ANN NEUROL 2023;93:743-751.
  • ||||||||||  Journal:  Prevalence of myasthenia gravis in Colombia. Reply (Pubmed Central) -  Mar 28, 2023   
    A prior neurological event should not necessarily preclude reimmunization and the decision to proceed with reimmunization should consider the overwhelming benefits conferred by vaccination toward ending this pandemic. No abstract available
  • ||||||||||  prednisone / Generic mfg., amphotericin b liposome / Generic mfg.
    Cryptococcal Empyema in an Immunocompromised Patient on Chronic Corticosteroid Therapy With Recent Colectomy: A Case Report (Walter E. Washington Convention Center, Area K, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_8108;    
    Perforated bowel and abdominal surgery have both been implicated as causes of fungal pleural effusions, but Cryptococcus is an uncommon organism in these settings.Case Presentation We present the case of a 77-year-old male with a history of myasthenia gravis, managed on 100mg daily of prednisone for several weeks, who presented with three weeks of progressive dyspnea, motor and cognitive decline, as well as diplopia and ptosis...He was started on liposomal amphotericin B and flucytosine...Immunocompromised state, disseminated disease, and recent abdominal surgery are all associated with increased incidence of fungal pleural effusions. This must remain a consideration in septic patients with no clear cause of infection.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    A Case of Pembrolizumab-induced Myasthenia-like Illness and Myositis (Walter E. Washington Convention Center, Area A, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_7963;    
    Unfortunately, recognition of this phenomenon as an adverse drug complication is limited. It has been reported that about 80% of cases improve with appropriate treatment, therefore, increased clinical awareness of this complication would be beneficial.It is also important to note that rapid clinical deterioration in the form of acute respiratory failure leading to respiratory arrest and eventually cardiopulmonary arrest can occur in the absence of appropriate and timely diagnosis and treatment.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    The Role of Dupilumab in Refractory Anaphylaxis Secondary to Food Allergy (Walter E. Washington Convention Center, Area A, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_7937;    
    IL4 and IL13 inhibition may have played a role in the resolution of this patient laryngeal edema. CONCLUSION This highlights a rare case of refractory anaphylaxis improvement with Dupilumab.
  • ||||||||||  Muscle or Junction: A Clinical Case of Respiratory Failure and Muscle Weakness (Walter E. Washington Convention Center, Area F, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_6416;    
    It is important to recognize early signs of respiratory failure due to the 4% mortality associated with myasthenic crisis. Diagnosis of neuromuscular conditions causing respiratory failure should include PFTs, which can demonstrate restrictive patterns, chest imaging to rule out other causes, and a broad autoimmune workup.Conclusion Neuromuscular causes of respiratory failure are uncommon, but, when patients develop associated muscle weakness, clinical suspicion should be high, and extensive workup should be pursued.
  • ||||||||||  Soliris (eculizumab) / AstraZeneca
    Biomarker, Journal:  Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders. (Pubmed Central) -  Mar 25, 2023   
    Recently, eculizumab, a humanized anti-C5 monoclonal antibody, has been clinically applied against neuroimmune diseases such as myasthenia gravis and neuromyelitis optica spectrum disorders (NMOSD)...Complement factor H (CFH), a complement regulatory factor, was decreased in the acute phase as well as in the remission phase of NMOSD, but not in any phases of GBS. Together, these findings suggest that complement biomarkers, such as Ba, sC5b-9 and CFH in peripheral blood, have potential utility in understanding the pathological status of NMOSD.
  • ||||||||||  Journal, IO biomarker:  Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis. (Pubmed Central) -  Mar 25, 2023   
    We conducted a bibliometric analysis of 9,970 original MG-related articles published between 1966 and 2022. Ultimately, we found that future MG research hotspots include two major parts: (1) studies directly related to MG disease itself: clinical trials of various targeted biological agents; the relationship between biomarkers and therapeutic decisions, pathogenesis and outcome events, ultimately serving individualized management or precision therapy; (2) studies related to MG and COVID-19: different variants of COVID-19 (e.g., Omicron) on MG adverse outcome events; assessment of the safety of different COVID-19 vaccines for different subtypes of MG.
  • ||||||||||  Journal, Metastases:  Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients. (Pubmed Central) -  Mar 24, 2023   
    Ultimately, we found that future MG research hotspots include two major parts: (1) studies directly related to MG disease itself: clinical trials of various targeted biological agents; the relationship between biomarkers and therapeutic decisions, pathogenesis and outcome events, ultimately serving individualized management or precision therapy; (2) studies related to MG and COVID-19: different variants of COVID-19 (e.g., Omicron) on MG adverse outcome events; assessment of the safety of different COVID-19 vaccines for different subtypes of MG. Immunotherapy elicited a response in thymoma patients; however, more attention should be paid to the immune-related adverse events.
  • ||||||||||  Journal:  Orthostatic dysarthria in myasthenia gravis. (Pubmed Central) -  Mar 24, 2023   
    Immunotherapy elicited a response in thymoma patients; however, more attention should be paid to the immune-related adverse events. No abstract available
  • ||||||||||  Retrospective data, Journal:  The Duke Myasthenia Gravis Clinic Registry: II. Analysis of Outcomes. (Pubmed Central) -  Mar 24, 2023   
    These results demonstrate outcomes that can be achieved in patients with MG treated according to the current Consensus Guidance statements. Among other things, they can be used to determine the added value and potential role of new treatment modalities developed since 2018.
  • ||||||||||  Retrospective data, Journal, HEOR:  Treatment patterns in myasthenia gravis: a United States health claims analysis. (Pubmed Central) -  Mar 21, 2023   
    Among other things, they can be used to determine the added value and potential role of new treatment modalities developed since 2018. Many patients experienced exacerbations and received rescue therapy despite treatment, suggesting current treatments may not provide adequate disease control for some patients and that additional treatment options should be explored.
  • ||||||||||  prednisone / Generic mfg.
    Journal:  Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis. (Pubmed Central) -  Mar 21, 2023   
    The substantial and durable improvements in HRQoL end points in this study demonstrate the broader benefit of treatment with efgartigimod beyond relief of immediate signs and symptoms of gMG. A new predictive nomograph and web-based survival calculator we developed show favorable applicability and accuracy in predicting long-term GFS in adult-onset OMG patients.
  • ||||||||||  Journal:  The Potential for Treg-Enhancing Therapies in Nervous System Pathologies. (Pubmed Central) -  Mar 21, 2023   
    An ever-broader role for Treg in control of neurologic disease has been shown for traumatic brain injury, stroke, neurotrophic pain, epilepsy, and psychiatric disorders. To such ends, this review serves to examine the role played by Tregs in nervous system diseases with a focus on harnessing their functional therapeutic role(s).
  • ||||||||||  mezagitamab (TAK-079) / Takeda
    Trial primary completion date:  A Study of TAK-079 in People With Generalized Myasthenia Gravis (clinicaltrials.gov) -  Mar 17, 2023   
    P2,  N=36, Completed, 
    We also discuss the essential parts of the diagnostic approach, and we provide general recommendations for the management of these disorders. Trial primary completion date: Mar 2022 --> Jul 2022
  • ||||||||||  Journal:  Treatment considerations in myasthenia gravis for the pregnant patient. (Pubmed Central) -  Mar 15, 2023   
    Other monoclonal IgG antibodies such as eculizumab and efgartigimod should be given only when regarded strictly necessary to avoid long-term and severe incapacity...Neonatal myasthenia manifests as a transient weakness caused by the mother's IgG muscle antibodies and affects 10% of babies. MG women should be supported in their wish to have children.
  • ||||||||||  Clinical, Retrospective data, Review:  Myasthenia Gravis and Vitamin D serum levels: A systematic review and Meta-analysis. (Pubmed Central) -  Mar 15, 2023   
    MG women should be supported in their wish to have children. There are statistically significant lower levels of Vitamin D in MG patients, so routine checking and possible correction should be advised in MG patients based on the current data.